Thomas Struengmann & family
Pharmaceuticals · Germany
Net worth, last 30 days
Biography
Thomas Struengmann and twin brother Andreas were early backers of German firm BioNTech, which partnered with Pfizer to make a vaccine for Covid-19.
The brothers cofounded generic drugmaker Hexal in 1986 and sold it to Novartis in 2005 for some $7 billion.
The brothers invest in biotech, pharma, life sciences and healthcare companies through their Zug, Switzerland-based investment firm, Santo Holding.
In 2008, they established a neuroscience research center in Frankfurt named after their father, Ernst Struengmann.
Did you know
After obtaining a business degree from the University of Augsburg, Thomas worked as a marketing manager for Schering-Plough.
Like his brother, an identical twin, he is said to be an accomplished golfer and likes to ski. He reportedly collects modern art and Swiss watches.
Holdings
| Company | Ticker | Shares | Value |
|---|---|---|---|
| BioNTech Sponsored ADR | BNTX-US | 50,640,000 | $4.1B |
| Formycon AG | FYB-DE | 2,124,000 | $30M |
| Private assets & other | $6.3B | ||